Z
Zhenfang Du
Researcher at Vanderbilt University Medical Center
Publications - 30
Citations - 1085
Zhenfang Du is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: DNA methylation & Methylation. The author has an hindex of 14, co-authored 27 publications receiving 713 citations. Previous affiliations of Zhenfang Du include Zhejiang University & The Chinese University of Hong Kong.
Papers
More filters
Journal ArticleDOI
Mechanisms of receptor tyrosine kinase activation in cancer.
Zhenfang Du,Christine M. Lovly +1 more
TL;DR: The processes whereby RTKs are activated under normal physiological conditions are reviewed and several mechanisms wherebyRTKs can be aberrantly activated in human cancers are discussed.
Journal ArticleDOI
Epigenetic inactivation of the CpG demethylase TET1 as a DNA methylation feedback loop in human cancers
Lili Li,Chen Li,Haitao Mao,Zhenfang Du,Wai-Yee Chan,Paul Murray,Bing Luo,Anthony T.C. Chan,Tony Mok,Francis K.L. Chan,Richard F. Ambinder,Qian Tao,Qian Tao +12 more
TL;DR: Ectopic expression of TET1 catalytic domain suppressed colony formation and induced apoptosis of tumor cells of multiple tissue types, supporting its role as a broad bona fide tumor suppressor.
Journal ArticleDOI
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.
Benjamin P. Brown,Yun-Kai Zhang,David Westover,Yingjun Yan,Huan Qiao,Vincent Huang,Zhenfang Du,Jarrod A. Smith,Jeffrey S. Ross,Vincent A. Miller,Siraj M. Ali,Lyudmila Bazhenova,Alexa B. Schrock,Jens Meiler,Jens Meiler,Christine M. Lovly +15 more
TL;DR: The results fundamentally reframe the problem of targeted therapy resistance from one focused on the “drug–resistance mutation” pair to onefocused on the“activating mutation–drug–drug-resistance mutations” trio, which has broad implications across clinical oncology.
Journal ArticleDOI
Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes.
Lili Li,Yuan Zhang,Yichao Fan,Kun Sun,Xianwei Su,Zhenfang Du,Sai Wah Tsao,T. Loh,Hao Sun,Anthony T.C. Chan,Yi Xin Zeng,Wai-Yee Chan,Francis K.L. Chan,Qian Tao +13 more
TL;DR: The NPC methylome shows a special high-degree CpG methylation epigenotype, similar to the Epstein-Barr virus-infected gastric cancer, indicating a critical epigenetic etiology for NPC pathogenesis.
Journal ArticleDOI
RET Germline Mutations Identified by Exome Sequencing in a Chinese Multiple Endocrine Neoplasia Type 2A/Familial Medullary Thyroid Carcinoma Family
Xiao-Ping Qi,Ju-Ming Ma,Zhenfang Du,Rong-Biao Ying,Jun Fei,Hang-Yang Jin,Jian-Shan Han,Jin-Quan Wang,Xiao-Ling Chen,Chun-Yue Chen,Wen-Ting Liu,Jia-Jun Lu,Jianguo Zhang,Xian-Ning Zhang +13 more
TL;DR: The results confirmed the successful clinical utility of whole exome sequencing, and the data suggested that the p.C634Y/V292M/R67H/R982C mutation of RET exhibited a more aggressive clinical phenotype than p.P.C 634Y or p.V292C, likely predisposed to FMTC.